Form 4 for DXCM Dexcom
Accepted 2021-08-02 00:00:00 ET · period of report 2021-07-30 · accession 0001093557-21-000193 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-08-02 | 2021-07-30 | DXCM | Leach Jacob Steven | EVP CTO | S - Sale | $476.70 | -12.1K | 70.6K | -15% | -$5.76M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-07-30 | S | D | 12,087 | $476.70 | 70,554 | D | — | — | (F1) On March 5, 2021, the reporting person adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Leach. The sale of shares set forth above were pursuant to the 10b5-1 Plan. (F2) Included in this number are 19,999 unvested restricted stock units, 7,171 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 7,832 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. |